A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.

被引：0
|
作者：
Omuro, Y.
Ikari, T.
Ishii, H.
Ozaka, M.
Suyama, M.
Matsumura, Y.
Itoi, T.
Egawa, N.
Yano, S.
Hanada, K.
Kimura, Y.
Ukita, T.
Ishida, Y.
Tani, M.
Ohoka, S.
Hirose, Y.
Hijioka, S.
Watanabe, R.
Ikeda, T.
Nakajima, T.
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[2] Tobu Chiiki Hosp, Tokyo, Japan
[3] Canc Inst Hosp, Tokyo, Japan
[4] Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
[5] Juntendo Univ Hosp, Tokyo, Japan
[6] Tokyo Med Univ, Tokyo 1608402, Japan
[7] Kanazawa Univ, Kanazawa, Ishikawa, Japan
[8] JA Onomichi Gen Hosp, Hiroshima, Japan
[9] Sapporo Med Univ Hosp, Sapporo, Hokkaido, Japan
[10] Toho Univ, Ohashi Med Ctr, Tokyo, Japan
[11] Kurume Univ Hosp, Kurume, Fukuoka, Japan
[12] Wakayama Med Univ Hosp, Wakayama, Japan
[13] Tokyo Med & Dent Univ Hosp, Tokyo, Japan
[14] Fukui Red Cross Hosp, Fukui, Japan
[15] Kumamoto Red Cross Hosp, Kumamoto, Japan
[16] Matsuyama Shimin Hosp, Matsuyama, Japan
[17] Yokosuka Kyosai Hosp, Yokosuka, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4029
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer.
    Stathopoulos, GP
    Aravantinos, G
    Syrigos, K
    Kalbakis, K
    Karvounis, N
    Papakotoulas, P
    Boukovinas, J
    Potamianou, A
    Polyzos, A
    Christophilakis, CH
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [42] A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
    El-Khoueiry, A. B.
    Ramanathan, R. K.
    Yang, D. Y.
    Zhang, W.
    Shibata, S.
    Wright, J. J.
    Gandara, D.
    Lenz, H. J.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1175 - 1183
  • [43] A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
    A. B. El-Khoueiry
    R. K. Ramanathan
    D. Y. Yang
    W. Zhang
    S. Shibata
    J. J. Wright
    D. Gandara
    H. J. Lenz
    Investigational New Drugs, 2012, 30 : 1175 - 1183
  • [44] A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer
    Takashi Sasaki
    Hiroyuki Isayama
    Yousuke Nakai
    Yukiko Ito
    Ichiro Yasuda
    Nobuo Toda
    Hirofumi Kogure
    Keiji Hanada
    Hiroyuki Maguchi
    Naoki Sasahira
    Hideki Kamada
    Tsuyoshi Mukai
    Yoshihiro Okabe
    Osamu Hasebe
    Iruru Maetani
    Kazuhiko Koike
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 973 - 979
  • [45] A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Ito, Yukiko
    Yasuda, Ichiro
    Toda, Nobuo
    Kogure, Hirofumi
    Hanada, Keiji
    Maguchi, Hiroyuki
    Sasahira, Naoki
    Kamada, Hideki
    Mukai, Tsuyoshi
    Okabe, Yoshihiro
    Hasebe, Osamu
    Maetani, Iruru
    Koike, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 973 - 979
  • [46] Gemcitabine plus S-1 for metastatic pancreatic cancer
    Zhu, Hong
    Yi, Cheng
    Zhao, Yaqin
    Gou, Hongfeng
    MEDICINE, 2018, 97 (41)
  • [47] Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
    Hagiwara, Yasuhiro
    Ohashi, Yasuo
    Okusaka, Takuji
    Ueno, Hideki
    Ioka, Tatsuya
    Boku, Narikazu
    Egawa, Shinichi
    Hatori, Takashi
    Furuse, Junji
    Mizumoto, Kazuhiro
    Ohkawa, Shinichi
    Yamaguchi, Taketo
    Yamao, Kenji
    Funakoshi, Akihiro
    Cheng, Ann-Lii
    Kihara, Kiyohiro
    Sato, Atsushi
    Tanaka, Masao
    ESMO OPEN, 2017, 2 (01)
  • [48] Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
    Kentaro Sudo
    Taketo Yamaguchi
    Kazuyoshi Nakamura
    Tadamichi Denda
    Taro Hara
    Takeshi Ishihara
    Osamu Yokosuka
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 249 - 254
  • [49] Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
    Sudo, Kentaro
    Yamaguchi, Taketo
    Nakamura, Kazuyoshi
    Denda, Tadamichi
    Hara, Taro
    Ishihara, Takeshi
    Yokosuka, Osamu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 249 - 254
  • [50] Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer
    Cao, Chunxiang
    Kuang, Meng
    Xu, Wei
    Zhang, Xunlei
    Chen, Jinfei
    Tang, Cuiju
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (12) : 1122 - 1130
12345